Press release
Gout Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical Trials, Treatment | DelveInsight
Curious about the latest updates in the Gout Pipeline? Click here to explore the therapies and trials making headlines @ Gout Pipeline Outlook Report [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Gout Pipeline Report
* On 01 October 2025, Amgen conducted a clinical trial is to assess efficacy, safety, blood levels and bodily effects of up to 2 dose levels of intravenous (IV) pegloticase (KRYSTEXXA) infusions at every 4 week intervals (Q4 Weeks) for up to 6 months (Day 1 to 24 weeks with an optional 24 - 48 weeks treatment duration) when given in combination with weekly oral doses of methotrexate (MTX). The goal is to identify an appropriate dose to be administered every 4 weeks to be used for future clinical trials for patients with chronic gout that does not adequately respond to conventional therapy.
* DelveInsight's Gout Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Gout treatment.
* The leading Gout Companies such as Swedish Orphan Biovitrum A, Arthrosi Therapeutics, Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., Protalix Biotherapeutics Inc., XORTX Therapeutics Inc, Insmed, Synlogic, Olatec Therapeutics LLC, JW Pharmaceutical, Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd, Shanton Pharma Pte. Ltd and others.
* Promising Gout Therapies such as Allopurinol, Dotinurad, Methotrexate, Pegloticase, ABP-671, D-0120, Lesinurad, DYV700 and others.
Want to know which companies are leading innovation in Gout? Dive into the full pipeline insights @ Gout Clinical Trials Assessment [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Gout Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Gout Pipeline Report also highlights the unmet needs with respect to the Gout.
Gout Overview
Gout, historically referred to as the ""disease of kings and king of diseases,"" is one of the most common causes of chronic inflammatory arthritis, particularly in the United States. It is defined by the deposition of monosodium urate crystals in joints and surrounding tissues, driven by hyperuricemia-serum urate levels exceeding 6.8 mg/dL, the solubility threshold of urate in blood. Clinically, gout can present as acute inflammatory arthritis flares, chronic joint damage (gouty arthropathy), tophaceous deposits, uric acid kidney stones, and chronic kidney disease. Despite its long-recognized history, gout remains a well-studied and manageable condition.
Gout Emerging Drugs Profile
* NASP: Swedish Orphan Biovitrum AB
NASP is a novel investigational medicine designed to reduce serum urate (SU) levels in people with uncontrolled gout, potentially reducing harmful tissue urate deposits which when left untreated can lead to debilitating gout flares and joint deformity. NASP is administered every 4-weeks as a sequential, two-component, infusion therapy consisting of tolerogenic nanoencapsulated sirolimus (NAS) which mitigates the formation of anti-drug antibodies (ADAs) and a uricase, pegadricase (P), which reduces serum uric acid. ADAs develop due to unwanted immune responses to biologic medicines, reducing their efficacy and tolerability, which remains an issue across multiple therapeutic modalities and disease states including uncontrolled gout. Sobi announced the initiation of a rolling Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for SEL-212. The submission is based on the results of the DISSOLVE I and II pivotal studies. SEL-212 is an innovative biologic therapy in development for the treatment of chronic refractory gout. This significant milestone follows the FDA's Fast Track designation of SEL-212, underscoring the urgent need for new treatment options for patients with chronic refractory gout. Currently, the drug is in Phase Preregistration stage of its development for the treatment of Gout.
* AR882: Arthrosi Therapeutics
AR882 is a potent and selective inhibitor of uric acid transporter 1 (URAT1), which is responsible for a majority of reabsorption of filtered uric acid from the renal tubular lumen. By inhibiting URAT1, AR882 increases uric acid urinary excretion and thereby lowers serum uric acid (sUA). Preclinically, AR882 has demonstrated inhibitory effect on uric acid uptake and good tolerability in pharmacology, pharmacokinetic and toxicology studies. Currently, the drug is in Phase III stage of its development for the treatment of Gout.
* ABP-671: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.
ABP-671 is an inhibitor of urate transporter 1 (URAT1) proteins, which are involved in reabsorption of uric acid by the kidneys. As a first line monotherapy, administered once a day in an oral tablet, ABP-671 reduces uric acid reabsorption, increasing its excretion in urine to reduce serum uric acid (sUA) levels. In long-term treatment this will reduce the number and size of tophi which will prevent gout attacks. By maintaining normal levels of sUA, the drug can also reduce the potential for complications associated with hyperuricemia, such as diabetes and heart and kidney disease. For the treatment of gout, there is a general agreement that targeting sUA levels of less than 6 and 5 mg/dL will inhibit the formation of new crystals and promote dissolution of existing crystals. Reduction of sUA levels to less than 5 mg/dL can further increase the velocity of tophi resolution, in both number and size. ABP-671 has demonstrated the ability to reach both sUA targets in a recent Phase IIa clinical trial. Approximately 93% and 77% of participants receiving ABP-671 treatment experienced reduction in sUA level to less than 6 and 5 mg/dL, respectively.. Currently, the drug is in Phase II/III stage of its development for the treatment of Gout.
* PRX-115: Protalix Biotherapeutics Inc.
PRX-115 is a recombinant PEGylated uricase enzyme, chemically modified enzyme in development for the potential treatment of uncontrolled gout.PRX-115 is our recombinant PEGylated uricase (urate oxidase), a chemically modified enzyme under development for the potential treatment of patients with uncontrolled gout. The uricase enzyme that does not exist naturally in humans converts uric acid to allantoin, which is easily eliminated through urine. This recombinant enzyme, expressed via our ProCellEx system, is designed to lower uric acid levels and improve clinical manifestation of the disease while having low immunogenicity and increased half-life of the drug in the blood. Pre-clinical data demonstrates long half-life, reduced immunogenic risk and high specific activity which supports the potential of PRX-115 to be a safe and effective treatment for patients with uncontrolled gout. One-month multiple dosing toxicity studies in two species and 6-month multiple dosing toxicity study in one specie were conducted to support single and multiple dose studies in humans. Currently, the drug is in Phase I stage of its development for the treatment of Gout.
If you're tracking ongoing Gout Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Gout Treatment Drugs [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Gout Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Gout with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gout Treatment.
* Gout Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Gout Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gout market.
Gout Companies
Swedish Orphan Biovitrum A, Arthrosi Therapeutics, Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., Protalix Biotherapeutics Inc., XORTX Therapeutics Inc, Insmed, Synlogic, Olatec Therapeutics LLC, JW Pharmaceutical, Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd, Shanton Pharma Pte. Ltd and others.
Gout Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Gout Products have been categorized under various Molecule types such as,
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
From emerging drug candidates to competitive intelligence, the Gout Pipeline Report covers it all - check it out now @ Gout Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Gout Pipeline Report
* Coverage- Global
* Gout Companies- Swedish Orphan Biovitrum A, Arthrosi Therapeutics, Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., Protalix Biotherapeutics Inc., XORTX Therapeutics Inc, Insmed, Synlogic, Olatec Therapeutics LLC, JW Pharmaceutical, Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd, Shanton Pharma Pte. Ltd and others.
* Gout Therapies- Allopurinol, Dotinurad, Methotrexate, Pegloticase, ABP-671, D-0120, Lesinurad, DYV700 and others.
* Gout Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Gout Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Gout Treatment landscape in this detailed analysis @ Gout Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/gouty-arthritis-gout-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Gout: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Gout- DelveInsight's Analytical Perspective
* Late Stage Products (Preregistration)
* NASP: Swedish Orphan Biovitrum A
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II/III)
* ABP-671: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* PRX-115: Protalix Biotherapeutics Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Gout Key Companies
* Gout Key Products
* Gout- Unmet Needs
* Gout- Market Drivers and Barriers
* Gout- Future Perspectives and Conclusion
* Gout Analyst Views
* Gout Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=gout-pipeline-drugs-report-2025-moa-emerging-therapies-clinical-trials-treatment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/gouty-arthritis-gout-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gout Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical Trials, Treatment | DelveInsight here
News-ID: 4230038 • Views: …
More Releases from ABNewswire
Sarcopenia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight E …
The Key Sarcopenia Companies in the market inlcude- TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others.
DelveInsight's "Sarcopenia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and…
Night Vision Disturbances Market Positioned for Accelerated Development Through …
The Key Night Vision Disturbances Companies in the market include - Ocuphire Pharma/Viatris, and others.
DelveInsight's "Night Vision Disturbances Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Night Vision Disturbances, historical and forecasted epidemiology as well as the Night Vision Disturbances market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of…
Psoriasis Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Ob …
The Key Psoriasis Companies in the market inlcude - UCB Pharma, Novartis, Sun Pharmaceutical/ Almirall, Bausch Health, Boehringer Ingelheim, LEO Pharma, AnaptysBio, Nimbus Lakshmi/Takeda, MoonLake Immunotherapeutics, Can-Fite Biopharma, E-nitiate Biopharmaceuticals, SFA Therapeutics, Rubedo Life Sciences, Inc, and others.
DelveInsight's "Psoriasis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Psoriasis, historical and forecasted epidemiology as well as the Psoriasis market trends in the United States, EU4 (Germany,…
Beta Thalassemia Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical T …
DelveInsight's "Beta Thalassemia Pipeline Insight 2025" report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in the Beta Thalassemia pipeline landscape. It covers the Beta Thalassemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Beta Thalassemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
More Releases for Gout
Chronic Gout Market Trends, Therapeutics, and Growth Opportunities
Chronic gout is a progressive form of arthritis characterized by elevated uric acid levels, leading to severe joint pain, inflammation, and long-term joint damage. This condition affects millions worldwide, often resulting in impaired mobility and reduced quality of life. With rising prevalence due to lifestyle changes, aging populations, and dietary habits, the Chronic Gout market is witnessing a surge in demand for advanced therapeutics, early diagnostics, and patient management solutions.
Download…
Chronic Gout Market Massive Growth opportunity Ahead
Introduction
Chronic gout is a form of arthritis characterized by recurrent attacks of severe pain, swelling, and inflammation in the joints, often due to the accumulation of uric acid crystals. This condition typically affects the big toe but can also impact other joints, including the knees, elbows, and wrists. Uric acid, a by-product of purine metabolism, accumulates in the body due to overproduction or underexcretion by the kidneys, leading to hyperuricemia…
Gout Market Innovations in Pain Management and Treatment
On April 08, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Gout Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many…
Gout Therapeutics Market Analysis By Drug Class (Nonsteroidal Anti-inflammatory …
Report Summary
The global gout therapeutics market was valued at USD 2.78 Billion in 2021 and is expected to grow at a CAGR of 13.7% during the forecast period 2023-2032.
Gout Therapeutics Market Introduction
The deposition of monosodium crystals (MSU) into the distal joints and peripheral tissues results in gout, an inflammatory arthritic disease. Gout is a typical type of painful inflammatory arthritis. One joint is typically affected at a time (often…
Global Gout Drugs Market Analysis (2020-2025)
Global Info Research offers a latest published report on Gout Drugs Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Gout Drugs Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
Click to view the full report TOC, figure and tables:
https://www.globalinforesearch.com/reports/371311/gout-drugs
Market…
Gout Therapeutics Market Emerging Trends And Forecast By 2025
Global Gout Therapeutics Market: Snapshot
The objective of treatment during a severe gout attack involves suppressing inflammation and controlling pain. The treatment of inflammation and pain can be attained with non-steroidal anti-inflammatory drugs, colchicine, or corticosteroids. The line of treatment chosen that would be suitable depends on the co-morbid medical conditions of the patient, side effect profile, and other medications.
Patients with multiple episodes of severe gout attacks every year or with…
